AR030197A1 - Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento - Google Patents

Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento

Info

Publication number
AR030197A1
AR030197A1 ARP010101310A ARP010101310A AR030197A1 AR 030197 A1 AR030197 A1 AR 030197A1 AR P010101310 A ARP010101310 A AR P010101310A AR P010101310 A ARP010101310 A AR P010101310A AR 030197 A1 AR030197 A1 AR 030197A1
Authority
AR
Argentina
Prior art keywords
alkyl
memory
manufacture
pharmaceutical composition
side chain
Prior art date
Application number
ARP010101310A
Other languages
English (en)
Inventor
Stanislaw Pikul
Norman Eugene Ohler
Neil Gregory Almstead
Steven Karl Laughlin
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR030197A1 publication Critical patent/AR030197A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto N-sustituido que contiene una cadena lateral heterocíclica que tiene una estructura segun la formula (1), en donde (A) R1 se selecciona de -OH, -NHOH; (B) R2 se selecciona de hidrogeno, alquilo, alquenilo y otros de acuerdo con la memoria; (C) R3 se selecciona de alquilo, alquenilo, alquinilo y otros de acuerdo con la memoria; (D) A es un heterociclolalquilo monocíclico sustituido o no sustituido que tiene de 3 a 8 átomos en el anillo de los cuales 1 a 3 son heteroátomos; o A está enlazada a R2 donde, juntos, forman un heterocicloalquilo monocíclico sustituido o no sustituido que tiene de 3 a 8 átomos en el anillo de los cuales 1 a 3 son heteroátomos; (E) n es de 0 a 4; (F) E se selecciona de un enlace covalente, alquilo C1-4, -C(=O)-, y otros de acuerdo con la memoria; (G) (1) X se selecciona de hidrogeno, alquilo y otros de acuerdo con la memoria; (H) G se selecciona de -S-, -O-, -N(R5)-, -C(R5)=C(R5')-, y otros de acuerdo con la memoria; (I) G' se selecciona de -S-, -O-, -N(R6)-, =C(R6)- y otros de acuerdo con la memoria; (J) M se selecciona de -CH- y -N-; y (K) Z es -(CH7R7)a-L-R8, donde: (1) a es de 0 a 4; (2) cada 7 y R7' independientemente se seleccionan de hidrogeno, alquilo y otros de acuerdo con la memoria; o un isomero optico, diastereomero o enantiomero para la formula (1), o una sal farmacéuticamente aceptable, o amida biohidrolizable, éster, o imida de estos. Una composicion farmacéutica que comprende: (a) una cantidad segura y eficaz de dicho compuesto; (b) un portador farmacéuticamente aceptable. El uso de un compuesto es que la fabricacion de un medicamento para tratar enfermedad asociada con la actividad no deseada de la metaloproteasa en un sujeto mamífero. Dicho uso en donde el trastorno es artritis, y se selecciona del grupo que consiste de osteoartritis y artritis reumatoide y otros de acuerdo con la memoria.
ARP010101310A 2000-03-21 2001-03-20 Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento AR030197A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19130200P 2000-03-21 2000-03-21

Publications (1)

Publication Number Publication Date
AR030197A1 true AR030197A1 (es) 2003-08-13

Family

ID=22704936

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101310A AR030197A1 (es) 2000-03-21 2001-03-20 Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento

Country Status (22)

Country Link
US (2) US6949545B2 (es)
EP (1) EP1265864A1 (es)
JP (1) JP2003528080A (es)
KR (1) KR20020081465A (es)
CN (1) CN1425004A (es)
AR (1) AR030197A1 (es)
AU (1) AU2001245891A1 (es)
BR (1) BR0109328A (es)
CA (1) CA2404131A1 (es)
CZ (1) CZ20023145A3 (es)
HU (1) HUP0300235A2 (es)
IL (1) IL151125A0 (es)
MA (1) MA26884A1 (es)
MX (1) MXPA02009311A (es)
NO (1) NO20024520D0 (es)
NZ (1) NZ520657A (es)
PE (1) PE20011137A1 (es)
PL (1) PL365444A1 (es)
RU (1) RU2245876C2 (es)
SK (1) SK12842002A3 (es)
WO (1) WO2001070691A1 (es)
ZA (1) ZA200206298B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304989T3 (es) * 1999-12-28 2008-11-01 Teikoku Seiyaku Co., Ltd. Agente antiprurigonoso para uso externo.
EP1265863A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
DE60236350D1 (de) * 2001-03-14 2010-06-24 Novartis Ag Azacycloalkyl-substituierte essigsäure-derivate zur verwendung als mmp-inhibitoren
US20070160655A1 (en) * 2003-04-23 2007-07-12 Sefton Michael V Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US20040213758A1 (en) * 2003-04-23 2004-10-28 Rimon Therapeutics Ltd. Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
KR100717022B1 (ko) * 2005-08-27 2007-05-10 삼성전자주식회사 잉크젯 프린트헤드 및 그 제조방법
NZ601350A (en) * 2007-11-16 2013-08-30 Abbvie Inc Method of treating arthritis
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP2376480B1 (en) * 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20100319773A1 (en) * 2009-06-22 2010-12-23 Solarmation, Inc. Optics for Concentrated Photovoltaic Cell

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
EP0623143A1 (en) 1992-01-15 1994-11-09 Merck & Co. Inc. Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
AU4267293A (en) 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69419473T2 (de) 1993-04-27 2000-03-16 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
WO1995004033A1 (en) 1993-08-02 1995-02-09 Celltech Limited Succinamide derivatives, processes for their preparation and their use as gelatinase and collagenase inhibitors
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
DK0822186T3 (da) 1994-01-20 2000-06-26 British Biotech Pharm L-tert-leucin-2-pyridylamid
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
JP3827324B2 (ja) 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5665753A (en) 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
ATE181055T1 (de) 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9412350D0 (en) 1994-06-20 1994-08-10 Fujisawa Pharmaceutical Co New compound and its preparation
NZ288298A (en) 1994-06-22 1998-12-23 British Biotech Pharm Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
AR002945A1 (es) 1994-11-15 1998-05-27 Bayer Corp Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
US5919940A (en) 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5573438A (en) * 1995-04-25 1996-11-12 D'andrea; Deborah Book including candy as a part of the pages
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6124333A (en) 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
JP3628335B2 (ja) * 1996-01-23 2005-03-09 塩野義製薬株式会社 スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤
EP0927156A1 (en) 1996-09-04 1999-07-07 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
EA002594B1 (ru) 1997-02-03 2002-06-27 Пфайзер Продактс Инк. Производные арилсульфониламиногидроксамовой кислоты
PT983267E (pt) * 1997-03-04 2005-06-30 Pharmacia Corp Compostos sulfonamida amidoaromaticas de acido hidroxamico
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
NZ503945A (en) * 1997-07-31 2002-11-26 Procter & Gamble Metalloprotease-inhibiting amide derivatives
DK0895988T3 (da) * 1997-08-08 2002-09-09 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
WO1999018079A1 (en) 1997-10-06 1999-04-15 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
HUP0101176A3 (en) 1998-02-04 2002-06-28 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases, process for their preparation and pharmaceutical compositions containing them
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
FR2782080B1 (fr) * 1998-08-10 2001-01-05 Adir Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6677360B2 (en) * 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
MXPA01008857A (es) 1999-03-03 2002-07-02 Procter & Gamble Inhibidores de metaloproteasa dihetero sustituidos.
CA2375524C (en) 1999-05-28 2006-11-28 Lawrence Alan Reiter 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
HN2000000052A (es) 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda

Also Published As

Publication number Publication date
SK12842002A3 (sk) 2003-02-04
NZ520657A (en) 2004-11-26
US20040127498A1 (en) 2004-07-01
IL151125A0 (en) 2003-04-10
CA2404131A1 (en) 2001-09-27
WO2001070691A1 (en) 2001-09-27
EP1265864A1 (en) 2002-12-18
MXPA02009311A (es) 2003-03-12
CZ20023145A3 (cs) 2003-01-15
AU2001245891A1 (en) 2001-10-03
BR0109328A (pt) 2003-06-10
HUP0300235A2 (hu) 2003-08-28
PL365444A1 (en) 2005-01-10
JP2003528080A (ja) 2003-09-24
KR20020081465A (ko) 2002-10-26
PE20011137A1 (es) 2001-12-04
NO20024520L (no) 2002-09-20
RU2002128007A (ru) 2004-02-27
CN1425004A (zh) 2003-06-18
MA26884A1 (fr) 2004-12-20
RU2245876C2 (ru) 2005-02-10
NO20024520D0 (no) 2002-09-20
US20030139414A1 (en) 2003-07-24
ZA200206298B (en) 2003-04-11
US6949545B2 (en) 2005-09-27

Similar Documents

Publication Publication Date Title
AR033356A1 (es) Compuesto que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
AR030197A1 (es) Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
CO4920241A1 (es) Compuestos inhibidores de metaloproteasas heterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO4900036A1 (es) Compuestos inhibidores de metaloproteasas de amina ciclica substituida composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO4920240A1 (es) Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
CO4900033A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas que los contienen .
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
AR047008A1 (es) Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos.
KR940014328A (ko) 인돌린 화합물
PA8610801A1 (es) Compuestos de aril o heteroaril amida
NO843836L (no) Terapeutisk aktive sulfamatderivater
PE58699A1 (es) Derivados de acido arilsulfonil hidroxamico
AR065937A2 (es) Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
CO4970730A1 (es) Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp
KR900004658A (ko) 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제
EA200000792A2 (ru) Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
EA199900135A1 (ru) Производные пиразолопиридина и их применение в качестве фармацевтического препарата
ATE18218T1 (de) Antifungische triazolyl-propanol-derivate.
AR019674A1 (es) Compuestos antitromboticos y composiciones farmaceuticas que los contienen
KR920000730A (ko) 신규 벤즈이미다졸 유도체, 그의 제조방법, 그의 신규 중간체, 그의 약물 용도 및 그를 함유하는 제약 조성물
ATE19773T1 (de) Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung.
EA199800155A1 (ru) Новое соединение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal